Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan Fowler, Sattva S. Neelapu, Veerabhadran Baladandayuthapani et al.|The Lancet Oncology|2014Cited by 263